We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Vergent Bioscience Stock

Invest in or calculate the value of your shares in Vergent Bioscience or other pre-IPO companies through EquityZen's platform.

Get Started

Vergent Bioscience Stock (VEBO)

Vergent Bioscience is a biotech company focusing on the development of tumor-targeted molecular imaging molecules for cancer surgery.

About Vergent Bioscience Stock

Founded

2016

Headquarters

Minneapolis, MN, US

Industries

Software, Artificial Intelligence, Data and Analytics

While the complete removal of residual cancer at the tumor margins during the surgical resection of solid tumors is closely linked with improved cure rates, it is often difficult for even experienced surgeons to distinguish cancerous tissue from normal tissue. Visual differentiation is needed at the cellular level. Vergent's molecularly-targeted imaging molecule, VGT-309, binds to enzymes that are overexpressed in tumor tissue, activating a brightly fluorescing dye. This proprietary molecule can identify and bind to multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. When injected prior to surgery, VGT-309 “lights up” cancerous tissue and gives the surgeon a clear visual guide for the removal procedure. Vergent’s approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic surgery procedures, while uniquely retaining the pricing flexibility required for success in a value-based healthcare system.
Locked Features

Join now and verify your accreditation status to gain access to:

  • Vergent Bioscience current valuation
  • Vergent Bioscience stock price
  • Available deals in Vergent Bioscience and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading Vergent Bioscience Stock

How to invest in Vergent Bioscience stock?

Accredited investors can buy pre-IPO stock in companies like Vergent Bioscience through EquityZen funds. These investments are made available by existing Vergent Bioscience shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Vergent Bioscience stock?

Shareholders can sell their Vergent Bioscience stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."